New drug duo shows early promise against advanced cancers

NCT ID NCT05021120

Completed Disease control Sponsor: Akesobio Australia Pty Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested a combination of two experimental drugs (AK127 and AK104) in 67 people with advanced or metastatic solid tumours that had stopped responding to standard treatments. The main goals were to check safety and find the right dose, while also looking for signs that the tumours shrank or stopped growing. The study is now complete, and results will help decide if further testing is warranted.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED OR METASTATIC SOLID TUMOURS

Contacts and locations

Show contact details

Locations

Ashford Cancer Centre Research

Adelaide, Australia
Austin Health

Melbourne, Australia
Monash Health

Melbourne, Australia
Southside Cancer Care Centre

Sydney, Australia
The Kinghorn Cancer Centre, St Vincents Hospital Sydney

Sydney, Australia